Frequent epigenetic inactivation of the receptor tyrosine kinase EphA5 by promoter methylation in human breast cancer.

EphA5 is a member of the Eph receptor tyrosine kinase family, which plays a critical role in the regulation of carcinogenesis. Our previous DNA methylation microarray results suggested that the CpG islands in the EphA5 promoter exhibited higher methylation levels in breast cancer tissues. In this study, we further analyzed EphA5 gene expression profiles, methylation status, and clinical implications in breast cancer. We found that the level of EphA5 mRNA was dramatically decreased in 5 different breast cancer cell lines. After treating the cell lines with 5-aza-2'-deoxycytidine (5-aza-dC, a demethylation agent), the levels of EphA5 mRNA and protein were significantly increased. Bisulfite sequencing and methylation-specific polymerase chain reaction detection showed that decreased expression of EphA5 was associated with its methylation status. We also found a significant correlation (P = .017) between the reduction of EphA5 mRNA levels and aberrant methylation of EphA5 in 31 paired tissue samples. In clinical samples, EphA5 methylation was detected in 64.1% (75/117) of breast tumors and 28.2% (33/117) of paired normal tissues (P < .001), which was associated with higher tumor grade (P = .024), lymph node metastasis (P = .004), and progesterone receptor-negative status (P = .008). Our data indicate that EphA5 might be a potential target for epigenetic silencing in primary breast cancer and a valuable molecular marker for breast cancer carcinogenesis and progression.

[1]  M. Kanamori,et al.  Downregulation of EphA7 by hypermethylation in colorectal cancer , 2005, Oncogene.

[2]  Jin Chen,et al.  EphA2 receptor tyrosine kinase as a promising target for cancer therapeutics. , 2005, Current cancer drug targets.

[3]  Dana M. Brantley-Sieders,et al.  A kinase-dependent role for EphA2 receptor in promoting tumor growth and metastasis , 2005, Oncogene.

[4]  A. Richardson,et al.  BRCA1 promoter methylation in sporadic breast tumors: relationship to gene expression profiles , 2005, Breast Cancer Research and Treatment.

[5]  J. Herman,et al.  Aberrant methylation of the estrogen receptor and E-cadherin 5' CpG islands increases with malignant progression in human breast cancer. , 2000, Cancer research.

[6]  Anthony Rhodes,et al.  American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. , 2006, Archives of pathology & laboratory medicine.

[7]  E. Batlle,et al.  Eph-ephrin signalling in adult tissues and cancer. , 2008, Current opinion in cell biology.

[8]  M. Szyf,et al.  DNA methylation and breast cancer. , 2004, Biochemical pharmacology.

[9]  G. Yancopoulos,et al.  Mistargeting hippocampal axons by expression of a truncated Eph receptor , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[10]  P. M. Das,et al.  DNA methylation and cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  G. Pelosi,et al.  Estrogen receptors in 699 primary breast cancers: A comparison of immunohistochemical and biochemical methods , 1995, Breast Cancer Research and Treatment.

[12]  M. Fackler,et al.  DNA methylation of RASSF1A, HIN‐1, RAR‐β, Cyclin D2 and Twist in in situ and invasive lobular breast carcinoma , 2003, International journal of cancer.

[13]  J. Frisén,et al.  Regulation of repulsion versus adhesion by different splice forms of an Eph receptor , 2000, Nature.

[14]  J. Herman,et al.  Gene silencing in cancer in association with promoter hypermethylation. , 2003, The New England journal of medicine.

[15]  M. Kinch,et al.  EphA2 overexpression decreases estrogen dependence and tamoxifen sensitivity. , 2003, Cancer research.

[16]  Manel Esteller,et al.  Methylation of p16(INK4a) promoters occurs in vivo in histologically normal human mammary epithelia. , 2003, Cancer research.

[17]  Dana M. Brantley-Sieders,et al.  The receptor tyrosine kinase EphA2 promotes mammary adenocarcinoma tumorigenesis and metastatic progression in mice by amplifying ErbB2 signaling. , 2008, The Journal of clinical investigation.

[18]  U. Lehmann,et al.  Quantitative assessment of promoter hypermethylation during breast cancer development. , 2002, The American journal of pathology.

[19]  R. Kandpal,et al.  Invasiveness of breast carcinoma cells and transcript profile: Eph receptors and ephrin ligands as molecular markers of potential diagnostic and prognostic application. , 2004, Biochemical and biophysical research communications.

[20]  K. Kullander,et al.  Mechanisms and functions of eph and ephrin signalling , 2002, Nature Reviews Molecular Cell Biology.

[21]  L. Ellis,et al.  Coexpression of ephrin‐Bs and their receptors in colon carcinoma , 2002, Cancer.

[22]  A. Andres,et al.  Expression of two novel eph-related receptor protein tyrosine kinases in mammary gland development and carcinogenesis. , 1994, Oncogene.

[23]  A. Boyd,et al.  Cloning and characterization of EphA3 (Hek) gene promoter: DNA methylation regulates expression in hematopoietic tumor cells. , 1999, Blood.

[24]  Eva K. Lee,et al.  Predicting aberrant CpG island methylation , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[25]  I. Ellis,et al.  Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. , 2002, Histopathology.

[26]  Donald E. Henson,et al.  Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases , 1989 .

[27]  R. Kandpal,et al.  Transcriptional silencing of EphB6 receptor tyrosine kinase in invasive breast carcinoma cells and detection of methylated promoter by methylation specific PCR. , 2006, Biochemical and biophysical research communications.

[28]  Elena B. Pasquale,et al.  The EphB4 receptor suppresses breast cancer cell tumorigenicity through an Abl–Crk pathway , 2006, Nature Cell Biology.

[29]  D. Bostwick,et al.  Overexpression of the EphA2 tyrosine kinase in prostate cancer , 1999, The Prostate.

[30]  H. Sugimura,et al.  Differential expression of EphA7 receptor tyrosine kinase in gastric carcinoma. , 2007, Human pathology.

[31]  S. Baylin,et al.  Methylation of the estrogen receptor gene CpG island marks loss of estrogen receptor expression in human breast cancer cells. , 1994, Cancer research.

[32]  Yue-zhong Wu,et al.  Global DNA methylation profiling reveals silencing of a secreted form of Epha7 in mouse and human germinal center B-cell lymphomas , 2007, Oncogene.

[33]  D. Harpole,et al.  Predictive value of the EphA2 receptor tyrosine kinase in lung cancer recurrence and survival. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.